|
시장보고서
상품코드
2087383
단백질 치료 시장 : 모달리티, 치료 영역, 투여 경로, 제형, 개발 단계, 치료 레지멘, 최종사용자, 환자 유형별 - 세계 예측(2026-2032년)Protein Therapeutics Market by Modality, Therapeutic Area, Route Of Administration, Dosage Form, Development Stage, Therapy Regimen, End User, Patient TYpe - Global Forecast 2026-2032 |
||||||
360iResearch
단백질 치료 시장은 2032년까지 CAGR 6.60%로 4,014억 3,000만 달러 규모로 확대할 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준연도 2025년 | 2,565억 4,000만 달러 |
| 추정연도 2026년 | 2,713억 5,000만 달러 |
| 예측연도 2032년 | 4,014억 3,000만 달러 |
| CAGR(%) | 6.60% |
단백질 치료는 전문적인 생물제제에서 현대 의학의 핵심으로 자리매김하고 있으며, 그 범위는 모노클로널 항체, 재조합 호르몬, 응고 인자, 효소, 융합 단백질, 사이토카인, 설계 펩티드에 달합니다. 수요를 지원하고 있는 것은 암, 자가면역질환, 당뇨병, 희귀 유전성 질환, 염증성 질환의 부담 증가에 더해, 규제 당국의 승인 및 임상 실무 지침에 기반한 표적화된 생물학적 기전에 대한 임상의들의 신뢰가 높아지고 있기 때문입니다.
이 부문은 높은 임상적 가치와 복잡한 바이오의약품의 제조, 품질, 안전성, 유효성, 약물 모니터링에 대한 엄격한 규제 요건이 특징입니다. 타사와의 차별화는 입증된 치료 효과, 지속적인 안전성, 제조 가능성, 투여 편의성, 지불자용 근거, 바이오시밀러, 피하 투여 제제, Fc 공학, 반감기 연장, 병용 요법 등의 수명주기 전략에 점점 더 의존하고 있습니다.
단백질 치료의 양상을 일변시키는 혁신적인 변화
단백질 치료 부문은 바이오의약품의 혁신, 바이오시밀러에 의한 경쟁, 병원에서 시행되는 정맥 주사 투여에서 환자 친화적인 투여 방식으로의 전환에 힘입어 그 양상이 새롭게 변화하고 있습니다. 피하 자동 주사기, 지속형 제제, 프리필드 주사기, 개선된 콜드 체인 시스템 덕분에 만성질환에 대한 접근성이 확대되는 동시에 치료 부담이 줄어들고 있습니다.
단백질 치료에 대한 인공지능의 누적 영향
인공지능(AI)은 단백질 치료제의 신약 발굴, 개발, 제조의 전 단계에서 실질적인 원동력으로 자리 잡고 있습니다. AI를 활용한 단백질 구조 예측, 서열 최적화, 개발 가능성 스크리닝, 에피토프 매핑, 면역원성 위험 평가는 검증된 실험 워크플로우와 결합함으로써, 연구팀이 후보 물질의 우선순위를 조기에 결정하고, 피할 수 있는 후기 단계의 실패를 줄이는 데 도움이 됩니다.
세계 단백질 치료 시장의 주요 지역별 분석
북미는 생명공학 분야에 대한 풍부한 자금 공급, 산학 간의 강력한 협력, 첨단 임상 검사 인프라, 생물제제 및 바이오시밀러에 관한 FDA와 캐나다 보건부의 확립된 승인 절차를 바탕으로, 단백질 치료 분야의 혁신을 주도하는 주요 거점으로 자리매김하고 있습니다. 미국은 생물제제의 연구, 전문 의료 분야로의 도입, 규제와 관련된 경험을 바탕으로 이 지역의 핵심 역할을 담당하고 있는 반면, 캐나다는 임상 연구 역량, 생물제제 제조에 대한 투자, 가치 기반 치료법에 대한 공적 의료제도의 수요를 창출하고 있습니다.
아세안(ASEAN), GCC, EU, 브릭스(BRICS), G7, 나토(NATO)에 관한 주요 그룹별 분석
G7 국가들은 높은 의료비 지출, 정교한 규제 체계, 잘 구축된 임상 검사 네트워크, 전문 의약품에 대한 광범위한 보험 적용을 통해 단백질 치료 분야를 지속적으로 주도하고 있습니다. 이러한 시장들은 임상 평가 지표, 비교 유효성, 안전성 모니터링, 환자 보고 결과, 수명주기관리에 관한 증거 기준을 정하고 있으며, 전 세계적인 시장 출시 순서 및 규제 전략을 수립하는 데 있으며, 필수적인 역할을 수행하고 있습니다.
단백질 치료의 도입 및 혁신에 관한 주요 국가들의 인사이트
미국은 주요 생명공학 클러스터, 풍부한 벤처 자금, 학술연구 역량, 생물제제, 바이오시밀러, 희귀질환 치료제, 획기적인 치료법에 관한 FDA의 풍부한 경험을 바탕으로 단백질 치료 분야의 주요 상업적 혁신 시장으로 자리매김하고 있습니다. 캐나다는 강력한 임상 연구 네트워크, 공적 보험 기관의 영향력, 바이오시밀러 사용 확대를 특징으로 합니다. 한편, 멕시코와 브라질은 공공 조달, 민간 전문 의료 서비스, 확대되는 암 및 당뇨병 치료 수요, 현지 규제의 현대화 등이 어우러져 라틴아메리카에서 중요한 접근 시장으로 자리매김하고 있습니다.
단백질 치료 산업의 리더를 위한 실천적 제안
업계 리더들은 차별화된 임상적 가치, 확장 가능한 제조 역량, 규제 당국, 보험사, 임상의, 환자 모두를 만족시키는 근거 기반 전략을 우선시해야 합니다. 개발 프로그램에서는 초기 단계부터 바이오마커를 통한 환자 선정, 면역원성 평가, 인적 요인 공학, 필요에 따라 소아 및 희귀 질환에 대한 배려, RWD(Real World Data)(REW) 계획을 통합해야 합니다.
단백질 치료 시장 분석을 위한 조사 기법
본 요약본은 공공 규제 당국, 동료 심사를 거친 생의학 문헌, 임상시험 등록 기관, 의료 기술 평가 기관, 의약품 안전성 모니터링 자료, 공중보건 데이터베이스 및 업계에서 널리 인정받는 간행물을 바탕으로 한 2차 문헌 조사를 기반으로 작성되었습니다. 본 분석에서는 생물제제의 승인, 바이오시밀러 정책, 제조 동향, 질병 부담, 임상 개발 활동, 지역별 의료 접근성 지표에서 도출된 증거에 중점을 두고 있습니다.
결론: 단백질 치료의 전략적 전망
정밀 의료, 바이오시밀러의 합리적인 가격, 첨단 바이오 제조 기술, 환자 중심의 투여 방식이 융합되는 가운데, 단백질 치료는 앞으로도 전략적으로 중요한 위치를 유지할 것으로 전망됩니다. 혁신이 임상적 요구, 지불 주체의 가치, 안정적인 공급, 규제 당국에 대한 신뢰, 만성질환 및 전문 질환에 대한 실용적인 투여 모델과 부합하는 부문에서 그 도입이 가장 활발하게 이루어질 것으로 보입니다.
자주 묻는 질문
목차
제1장 서문
제2장 조사 방법
제3장 개요
제4장 시장 개요
제5장 시장 인사이트
제6장 AI의 누적 영향, 2026년
제7장 단백질 치료 시장 : 모달리티별
제8장 단백질 치료 시장 : 치료 영역별
제9장 단백질 치료 시장 : 투여 경로별
제10장 단백질 치료 시장 : 제형별
제11장 단백질 치료 시장 : 개발 단계별
제12장 단백질 치료 시장 : 치료 레지멘별
제13장 단백질 치료 시장 : 최종사용자별
제14장 단백질 치료 시장 : 환자 유형별
제15장 단백질 치료 시장 : 지역별
제16장 단백질 치료 시장 : 그룹별
제17장 단백질 치료 시장 : 국가별
제18장 경쟁 구도
제19장 기업 개요
KSA 26.07.21The Protein Therapeutics Market is projected to grow by USD 401.43 billion at a CAGR of 6.60% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 256.54 billion |
| Estimated Year [2026] | USD 271.35 billion |
| Forecast Year [2032] | USD 401.43 billion |
| CAGR (%) | 6.60% |
Protein therapeutics have moved from specialist biologics into a core pillar of modern medicine, spanning monoclonal antibodies, recombinant hormones, clotting factors, enzymes, fusion proteins, cytokines, and engineered peptides. Demand is supported by the rising burden of cancer, autoimmune disease, diabetes, rare genetic disorders, and inflammatory conditions, alongside increasing clinician confidence in targeted biologic mechanisms supported by regulatory approvals and clinical practice guidelines.
The sector is shaped by high clinical value, complex biologics manufacturing, and rigorous regulatory expectations for quality, safety, efficacy, and pharmacovigilance. Differentiation increasingly depends on proven outcomes, durable safety, manufacturability, delivery convenience, payer evidence, and lifecycle strategies such as biosimilars, subcutaneous formulations, Fc engineering, half-life extension, and combination regimens.
Transformative Shifts Reshaping Protein Therapeutics
The protein therapeutics landscape is being reshaped by biologics innovation, biosimilar competition, and the shift from hospital-based infusions toward patient-friendly delivery. Subcutaneous auto-injectors, long-acting formulations, prefilled syringes, and improved cold-chain systems are expanding access while reducing treatment burden for chronic diseases.
At the same time, regulatory agencies are encouraging quality-by-design, comparability science, pharmacovigilance, and real-world evidence to support approvals and post-market confidence. Manufacturers are investing in continuous bioprocessing, single-use technologies, high-throughput analytics, closed-system operations, and resilient supply networks to manage cost, capacity, contamination risk, and product consistency.
Cumulative Impact of Artificial Intelligence on Protein Therapeutics
Artificial intelligence is becoming a practical accelerator across protein therapeutics discovery, development, and manufacturing. AI-enabled protein structure prediction, sequence optimization, developability screening, epitope mapping, and immunogenicity risk assessment help teams prioritize candidates earlier and reduce avoidable late-stage failures when supported by validated experimental workflows.
In operations, machine learning supports bioprocess monitoring, deviation detection, yield optimization, predictive maintenance, and quality analytics across upstream and downstream manufacturing. The highest-value use cases are emerging where AI is paired with validated laboratory data, regulatory-grade documentation, data governance, and human expert review rather than treated as a replacement for experimental evidence.
Key Regional Insights Across Global Protein Therapeutics Markets
North America remains a leading center for protein therapeutics innovation due to deep biotechnology financing, strong academic-industry collaboration, advanced clinical trial infrastructure, and established FDA and Health Canada pathways for biologics and biosimilars. The United States anchors the region through biologics research, specialty care adoption, and regulatory experience, while Canada contributes clinical research capacity, biologics manufacturing investments, and public health-system demand for value-based therapies.
Europe combines a mature regulatory environment, significant biomanufacturing expertise, and strong adoption of biosimilars through national reimbursement systems. The European Union supports harmonized scientific review, centralized biologics assessment, and cross-border pharmacovigilance, while the United Kingdom, Germany, France, Italy, and Spain represent major markets for autoimmune, oncology, metabolic, hematology, and rare-disease protein therapies.
Asia-Pacific is expanding as China, Japan, India, South Korea, Australia, and ASEAN markets build clinical development capacity, domestic biologics manufacturing, and biosimilar portfolios supported by regulatory modernization and healthcare investment. Latin America is led by Brazil and Mexico, where public procurement, private specialty care, pharmacovigilance capacity, and reimbursement policy influence uptake. The Middle East, particularly GCC countries, is investing in specialty healthcare, hospital infrastructure, and biologics access, while Africa's opportunity is tied to affordability, cold-chain expansion, regulatory strengthening, local distribution partnerships, and programs that improve availability of essential biologics.
Key Group Insights for ASEAN, GCC, EU, BRICS, G7, and NATO
The G7 continues to shape protein therapeutics through high healthcare spending, advanced regulatory systems, sophisticated clinical trial networks, and broad reimbursement for specialty medicines. These markets set evidence expectations for clinical endpoints, comparative effectiveness, safety monitoring, patient-reported outcomes, and lifecycle management, making them essential for global launch sequencing and regulatory strategy.
The European Union is influential through centralized biologics regulation, biosimilar adoption, health technology assessment practices, and cross-border pharmacovigilance standards. BRICS economies are increasingly important because of large patient populations, expanding biologics production, growing clinical trial participation, and rising demand for oncology, diabetes, autoimmune, and rare-disease therapies, although pricing pressure, reimbursement constraints, and access disparities remain material.
ASEAN markets are gaining relevance as governments improve universal health coverage, local manufacturing incentives, hospital biologics access, and biologics regulatory capacity. GCC countries are investing in advanced specialty care, national procurement modernization, and cold-chain logistics for high-value medicines, while NATO member markets overlap substantially with high-income healthcare systems where supply resilience, domestic production, cybersecurity, and secure pharmaceutical logistics are strategic priorities.
Key Country Insights in Protein Therapeutics Adoption and Innovation
The United States is the primary commercial and innovation market for protein therapeutics, supported by major biotechnology clusters, extensive venture funding, academic research strength, and significant FDA experience with biologics, biosimilars, orphan medicines, and breakthrough therapies. Canada offers strong clinical research networks, public payer influence, and increasing biosimilar use, while Mexico and Brazil represent important Latin American access markets shaped by public procurement, private specialty care, expanding oncology and diabetes treatment demand, and local regulatory modernization.
In Europe, the United Kingdom, Germany, France, Italy, and Spain combine high disease diagnosis rates, sophisticated specialist care, and established reimbursement systems. Germany is notable for early market access and biomanufacturing strength; France emphasizes health technology assessment and national access policies; the United Kingdom supports translational research, clinical trial infrastructure, and value assessment; Italy and Spain contribute large patient pools and growing biosimilar penetration. Russia remains a distinct market with local production priorities, import substitution policies, and regulatory complexity.
Across Asia-Pacific, China has become a major force in biologics development, clinical trials, domestic innovation, and biosimilar competition. India is recognized for cost-efficient biopharmaceutical manufacturing, biosimilar development, and expanding domestic demand for diabetes, oncology, and inflammatory disease treatments. Japan maintains high regulatory standards, strong pharmacovigilance, and adoption of innovative therapies for oncology and rare disease. South Korea is a global biosimilar and contract manufacturing hub, while Australia contributes high-quality clinical research, reimbursement discipline, and early-phase trial capabilities.
Actionable Recommendations for Protein Therapeutics Industry Leaders
Industry leaders should prioritize differentiated clinical value, scalable manufacturing, and evidence strategies that satisfy regulators, payers, clinicians, and patients. Development programs should integrate biomarker-led patient selection, immunogenicity assessment, human factors engineering, pediatric and rare-disease considerations where relevant, and real-world evidence plans from the earliest stages.
Organizations should build resilient supply chains through dual sourcing, cold-chain visibility, technology transfer readiness, regional manufacturing partnerships, and contamination-control systems aligned with good manufacturing practice. Commercial teams need pricing and access strategies that account for biosimilar pressure, outcomes-based reimbursement, and patient support programs, while R&D teams should use AI responsibly with auditable datasets, model validation, and experimental confirmation.
Research Methodology for Protein Therapeutics Market Analysis
This executive summary is based on secondary research from public regulatory agencies, peer-reviewed biomedical literature, clinical trial registries, health technology assessment bodies, pharmacovigilance resources, public health databases, and recognized industry publications. The analysis emphasizes evidence from biologics approvals, biosimilar policy, manufacturing trends, disease burden, clinical development activity, and regional healthcare access indicators.
Insights are synthesized through regulatory review, competitive benchmarking, technology adoption assessment, and qualitative evaluation of healthcare access conditions. The methodology prioritizes verifiable, non-speculative findings and avoids unsupported market-size, market-share, or forecasting claims, ensuring that strategic conclusions are grounded in observable industry developments.
Conclusion: Strategic Outlook for Protein Therapeutics
Protein therapeutics are positioned for continued strategic importance as precision medicine, biosimilar affordability, advanced biomanufacturing, and patient-centered delivery converge. Adoption will be strongest where innovation aligns with clinical need, payer value, reliable supply, regulatory confidence, and practical administration models for chronic and specialty diseases.
The next phase of competition will reward organizations that combine biologic science with manufacturing excellence, AI-enabled decision support, pharmacovigilance discipline, and region-specific access strategies. Stakeholders that prove differentiated outcomes while improving affordability, convenience, and supply reliability will be best placed to capture long-term opportunity in global protein therapeutics.
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. Market Share Analysis, 2025
- 3.5. FPNV Positioning Matrix, 2025
- 3.6. New Revenue Opportunities
- 3.7. Next-Generation Business Models
- 3.8. Industry Roadmap
4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
- 4.4. Porter's Five Forces Analysis
- 4.5. PESTLE Analysis
- 4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
- 4.7. Go-to-Market Strategy
5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Protein Therapeutics Market, by Modality
- 7.1. Enzymes
- 7.1.1. Plasminogen Activators
- 7.1.2. Uricase
- 7.2. Fusion Proteins
- 7.2.1. Cytokine Fusion
- 7.2.2. Fc Fusion
- 7.3. Hormones
- 7.3.1. Growth Hormone
- 7.3.2. Insulin
- 7.3.3. Thyroid Hormones
- 7.4. Interferons
- 7.4.1. Interferon Alpha
- 7.4.2. Interferon Beta
- 7.4.3. Interferon Gamma
- 7.5. Monoclonal Antibodies
- 7.5.1. Chimeric
- 7.5.2. Fully Human
- 7.5.3. Humanized
- 7.5.4. Murine
- 7.6. Recombinant Proteins
- 7.6.1. Erythropoietin
- 7.6.2. Growth Hormones
- 7.6.3. Insulin Analogues
- 7.7. Vaccines
- 7.7.1. Conjugate
- 7.7.2. Inactivated
- 7.7.3. Live Attenuated
- 7.7.4. Subunit
8. Protein Therapeutics Market, by Therapeutic Area
- 8.1. Endocrinology
- 8.1.1. Diabetes
- 8.1.2. Growth Disorders
- 8.2. Immunology
- 8.2.1. Autoimmune Disorders
- 8.2.2. Inflammatory Disorders
- 8.3. Infectious Diseases
- 8.3.1. Bacterial Infections
- 8.3.2. Viral Infections
- 8.4. Oncology
- 8.4.1. Hematological Malignancies
- 8.4.1.1. Leukemia
- 8.4.1.2. Lymphoma
- 8.4.2. Solid Tumors
- 8.4.2.1. Breast Cancer
- 8.4.2.2. Colorectal Cancer
- 8.4.2.3. Lung Cancer
- 8.4.1. Hematological Malignancies
- 8.5. Rare Diseases
- 8.5.1. Genetic Disorders
- 8.5.2. Lysosomal Storage Disorders
9. Protein Therapeutics Market, by Route Of Administration
- 9.1. Non Parenteral
- 9.1.1. Nasal
- 9.1.2. Oral
- 9.1.3. Transdermal
- 9.2. Parenteral
- 9.2.1. Intramuscular
- 9.2.2. Intravenous
- 9.2.3. Subcutaneous
10. Protein Therapeutics Market, by Dosage Form
- 10.1. Auto Injectors
- 10.2. Cartridges
- 10.3. Liquid
- 10.4. Lyophilized
- 10.5. Pen Injectors
- 10.6. Pre Filled Syringes
11. Protein Therapeutics Market, by Development Stage
- 11.1. Discovery
- 11.2. Preclinical
- 11.3. Phase I
- 11.4. Phase II
- 11.5. Phase III
- 11.6. Approved
12. Protein Therapeutics Market, by Therapy Regimen
- 12.1. Monotherapy
- 12.2. Combination Therapy
13. Protein Therapeutics Market, by End User
- 13.1. Ambulatory Surgical Centers
- 13.2. Clinics
- 13.2.1. Community Clinics
- 13.2.2. Specialty Clinics
- 13.3. Homecare
- 13.4. Hospitals
- 13.4.1. Private Hospitals
- 13.4.2. Public Hospitals
- 13.5. Research Institutes
14. Protein Therapeutics Market, by Patient TYpe
- 14.1. Pediatric
- 14.2. Adult
- 14.3. Geriatric
15. Protein Therapeutics Market, by Region
- 15.1. Asia-Pacific
- 15.2. North America
- 15.3. Latin America
- 15.4. Europe
- 15.5. Middle East
- 15.6. Africa
16. Protein Therapeutics Market, by Group
- 16.1. ASEAN
- 16.2. GCC
- 16.3. European Union
- 16.4. BRICS
- 16.5. G7
- 16.6. NATO
17. Protein Therapeutics Market, by Country
- 17.1. United States
- 17.2. Canada
- 17.3. Mexico
- 17.4. Brazil
- 17.5. United Kingdom
- 17.6. Germany
- 17.7. France
- 17.8. Russia
- 17.9. Italy
- 17.10. Spain
- 17.11. China
- 17.12. India
- 17.13. Japan
- 17.14. Australia
- 17.15. South Korea
18. Competitive Landscape
- 18.1. Market Concentration Analysis, 2025
- 18.1.1. Concentration Ratio (CR)
- 18.1.2. Herfindahl Hirschman Index (HHI)
- 18.2. Recent Developments & Impact Analysis, 2025
- 18.3. Product Portfolio Analysis, 2025
- 18.4. Benchmarking Analysis, 2025
19. Company Profiles
- 19.1. AbbVie Inc.
- 19.2. Alexion Pharmaceuticals, Inc.
- 19.3. Amgen Inc.
- 19.4. AstraZeneca PLC
- 19.5. Bayer AG
- 19.6. Biogen Inc.
- 19.7. Boehringer Ingelheim International GmbH
- 19.8. Bristol-Myers Squibb Company
- 19.9. Chugai Pharmaceutical Co., Ltd.
- 19.10. CSL Behring LLC
- 19.11. Eli Lilly and Company
- 19.12. F. Hoffmann-La Roche Ltd
- 19.13. Genentech, Inc.
- 19.14. Gilead Sciences, Inc.
- 19.15. GlaxoSmithKline PLC
- 19.16. Johnson & Johnson Services, Inc.
- 19.17. Kyowa Kirin Co., Ltd.
- 19.18. Merck Sharp & Dohme LLC
- 19.19. Novartis AG
- 19.20. Novo Nordisk A/S
- 19.21. Pfizer Inc.
- 19.22. Regeneron Pharmaceuticals, Inc.
- 19.23. Samsung Biologics Co., Ltd.
- 19.24. Sandoz International GmbH
- 19.25. Sanofi S.A.
- 19.26. Shionogi & Co., Ltd.
- 19.27. Takeda Pharmaceutical Company Limited
- 19.28. Teva Pharmaceutical Industries Ltd.
- 19.29. UCB S.A.
- 19.30. Vertex Pharmaceuticals Incorporated
